Managing Anemia: Point of Convergence for Heart Failure and Chronic Kidney Disease?

• Published in: Life (Basel, Switzerland) Switzerland), 2023-06, Vol.13 (6), p.1311
• Main Authors: Buliga-Finis, Oana Nicoleta, Ouatu, Anca, Tanase, Daniela Maria, Gosav, Evelina Maria, Seritean Isac, Petronela Nicoleta, Richter, Patricia, Rezus, Ciprian
• Format: Article
• Language: English
• Subjects: Anemia; Antagonists; Bone marrow; cardiorenal syndrome; Care and treatment; Chronic illnesses; Chronic kidney failure; Clinical trials; Complications and side effects; Congestive heart failure; Cytokines; Diagnosis; erythropoiesis-stimulating agents; Erythropoietin; Heart failure; Hemodialysis; Hemodynamics; Hemoglobin; Hepcidin; hepcidin antagonists; HIF-PH inhibitors; Hypoxia; Hypoxia-inducible factors; Inflammation; Iron; iron therapy; Kidney diseases; Kidneys; Morbidity; Mortality; Oxidative stress; Patients; Pharmacology; Prolyl hydroxylase; Quality of life; Renal failure; Renal function; Review; Tumor necrosis factor-TNF; Vasodilation
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life13061311

The pathologic triangle formed by chronic heart failure (HF), chronic kidney disease (CKD), and anemia carries high morbidity and mortality rates and decreases quality of life. Anemia represents a common condition in patients with advanced HF and CKD, with a total prevalence in cardiorenal syndrome (CRS) ranging from 5% to 55%. Searching for a pragmatic approach for these patients with guided and disease-specific recommendations beyond just targeted hemoglobin therapeutic behavior represents the core of research for ongoing clinical trials. It is well known that the prevalence of anemia increases with the advancement of CKD and HF. The physiopathological mechanisms of anemia, such as the reduction of endogenous erythropoietin and the decrease in oxygen transport, are leading to tissue hypoxia, peripheral vasodilation, stimulating neurohormonal activity, and maintenance of the progressive renal and cardiac dysfunction. Given the challenges with the treatment options for patients with cardiorenal anemia syndrome (CRSA), new therapeutic agents such as hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PH) or hepcidin antagonists are emerging in the light of recent research. This review summarizes the potential therapeutic tools for anemia therapy in the cardiorenal population.